Prediagnostic circulating metabolites in female breast cancer cases with low and high mammographic breast density.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 06 2021
22 06 2021
Historique:
received:
09
04
2021
accepted:
11
06
2021
entrez:
23
6
2021
pubmed:
24
6
2021
medline:
28
10
2021
Statut:
epublish
Résumé
Mammographic breast density (MBD) is a strong independent risk factor for breast cancer (BC). We designed a matched case-case study in the EPIC Florence cohort, to evaluate possible associations between the pre-diagnostic metabolomic profile and the risk of BC in high- versus low-MBD women who developed BC during the follow-up. A case-case design with 100 low-MBD (MBD ≤ 25%) and 100 high-MDB BC cases (MBD > 50%) was performed. Matching variables included age, year and type of mammographic examination.
Identifiants
pubmed: 34158597
doi: 10.1038/s41598-021-92508-1
pii: 10.1038/s41598-021-92508-1
pmc: PMC8219761
doi:
Substances chimiques
Lipids
0
Lipoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13025Références
McCormack, V. A. & dos Santos, S. I. Breast density and parenchymal patterns as markers of breast cancer risk: A meta-analysis. Cancer Epidemiol. Biomark. Prev. 15, 1159–1169 (2006).
doi: 10.1158/1055-9965.EPI-06-0034
Assi, V., Warwick, J., Cuzick, J. & Duffy, S. W. Clinical and epidemiological issues in mammographic density. Nat. Rev. Clin. Oncol. 9, 33–40 (2011).
pubmed: 22143145
doi: 10.1038/nrclinonc.2011.173
Boyd, N. F., Martim, L. J., Yaffe, M. J. & Minkin, S. Mammographic density and breast cancer risk: Current understanding and future prospects. Breast Cancer Res. 13, 223 (2011).
pubmed: 22114898
pmcid: 3326547
doi: 10.1186/bcr2942
Yaghjyan, L., Colditz, G. A., Rosner, B. & Tamimi, R. M. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to the time since the mammogram. Cancer Epidemiol. Biomark. Prev. 22, 1110–1117 (2013).
doi: 10.1158/1055-9965.EPI-13-0169
Rutter, C. M., Mandelson, M. T., Laya, M. B., Seger, D. J. & Taplin, S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 285, 171–176 (2001).
pubmed: 11176809
doi: 10.1001/jama.285.2.171
Boyd, N. F. Mammographic density and risk of breast cancer. Am. Soc. Clin. Oncol. Educ. Book https://doi.org/10.1200/EdBook_AM.2013.33.e57 (2013).
doi: 10.1200/EdBook_AM.2013.33.e57
pubmed: 23714456
Rinaldi, S. et al. Circulating concentrations of insulin-like growth factor-I, insulin-like growth factor-binding protein-3, genetic polymorphisms and mammographic density in premenopausal Mexican women: Results from the ESMaestras cohort. Int. J. Cancer 134, 1436–1444 (2014).
pubmed: 24037648
doi: 10.1002/ijc.28469
Soguel, L., Durocher, F., Tchernof, A. & Diorio, C. Adiposity, breast density, and breast cancer risk: Epidemiological and biological considerations. Eur. J. Cancer Prev. 26, 511–520 (2017).
pubmed: 27571214
pmcid: 5627530
doi: 10.1097/CEJ.0000000000000310
Shaikh, A. J. et al. Mammographic breast density and breast cancer molecular subtypes: The Kenyan–African aspect. Biomed. Res. Int. 2018, 6026315 (2018).
pubmed: 29607324
pmcid: 5828539
doi: 10.1155/2018/6026315
van der Waal, D., Verbeek, A. L. M. & Broeders, M. J. M. Breast density and breast cancer-specific survival by detection mode. BMC Cancer 18, 386 (2018).
pubmed: 29618328
pmcid: 5885304
doi: 10.1186/s12885-018-4316-7
Bertrand, K. A. et al. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res. 15, R104 (2013).
pubmed: 24188089
pmcid: 3978749
doi: 10.1186/bcr3570
Bertrand, K. A. et al. Dense and nondense mammographic area and risk of breast cancer by age and tumor characteristics. Cancer Epidemiol. Biomark. Prev. 24, 798–809 (2015).
doi: 10.1158/1055-9965.EPI-14-1136
Ding, J., Warren, R., Girling, A., Thompson, D. & Easton, D. Mammographic density, estrogen receptor status and other breast cancer tumor characteristics. Breast J. 16, 279–289 (2010).
pubmed: 20408823
doi: 10.1111/j.1524-4741.2010.00907.x
Razzaghi, H. et al. Association between mammographic density and basal-like and luminal A breast cancer subtypes. Breast Cancer Res. 15, R76 (2013).
pubmed: 24008056
pmcid: 3978452
doi: 10.1186/bcr3470
Conroy, S. M., Pagano, I., Kolonel, L. N. & Maskarinec, G. Mammographic density and hormone receptor expression in breast cancer: The Multiethnic Cohort Study. Cancer Epidemiol. 35, 448–452 (2011).
pubmed: 21247819
pmcid: 3142304
doi: 10.1016/j.canep.2010.11.011
Ma, H. et al. Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol. Biomark. Prev. 18, 479–485 (2009).
doi: 10.1158/1055-9965.EPI-08-0805
Heusinger, K. et al. Association of mammographic density with hormone receptors in invasive breast cancers: Results from a case-only study. Int. J. Cancer 131, 2643–2649 (2012).
pubmed: 22392346
doi: 10.1002/ijc.27515
Shawky, M. S. et al. A review of the influence of mammographic density on breast cancer clinical and pathological phenotype. Breast Cancer Res. Treat. 177, 251–276 (2019).
pubmed: 31177342
doi: 10.1007/s10549-019-05300-1
Nicholson, J. K. & Lindon, J. C. Systems biology: Metabonomics. Nature 455, 1054–1056 (2008).
pubmed: 18948945
doi: 10.1038/4551054a
Ali, S. E., Farag, M. A., Holvoet, P., Hanafi, R. S. & Gad, M. Z. A comparative metabolomics approach reveals early biomarkers for metabolic response to acute myocardial infarction. Sci. Rep. 6, 1–14 (2016).
doi: 10.1038/srep36359
Brindle, J. T. et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med. 8, 1439–1444 (2002).
pubmed: 12447357
doi: 10.1038/nm1202-802
Vignoli, A. et al. High-throughput metabolomics by 1D NMR. Angew. Chem. Int. Ed. Engl. 58, 968–994 (2019).
pubmed: 29999221
doi: 10.1002/anie.201804736
Takis, P. G., Ghini, V., Tenori, L., Turano, P. & Luchinat, C. Uniqueness of the NMR approach to metabolomics. Trends Anal. Chem. 120, 115300 (2019).
doi: 10.1016/j.trac.2018.10.036
Spratlin, J. L., Serkova, N. J. & Eckhardt, S. G. Clinical applications of metabolomics in oncology: A review. Clin. Cancer Res. 15, 431–440 (2009).
pubmed: 19147747
pmcid: 2676437
doi: 10.1158/1078-0432.CCR-08-1059
Silva, C., Perestrelo, R., Silva, P., Tomás, H. & Câmara, J. S. Breast cancer metabolomics: From analytical platforms to multivariate data analysis. A review. Metabolites 9, 102 (2019).
pmcid: 6572290
doi: 10.3390/metabo9050102
McCartney, A. et al. Metabolomics in breast cancer: A decade in review. Cancer Treat. Rev. 67, 88–96 (2018).
pubmed: 29775779
doi: 10.1016/j.ctrv.2018.04.012
Shen, J., Yan, L., Liu, S., Ambrosone, C. B. & Zhao, H. Plasma metabolomic profiles in breast cancer patients and healthy controls: By race and tumor receptor subtypes. Transl. Oncol. 6, 757–765 (2013).
pubmed: 24466379
pmcid: 3890711
doi: 10.1593/tlo.13619
Asiago, V. M. et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 70, 8309–8318 (2010).
pubmed: 20959483
pmcid: 2995269
doi: 10.1158/0008-5472.CAN-10-1319
McCartney, A. et al. Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. NPJ Breast Cancer 5, 26 (2019).
pubmed: 31482106
pmcid: 6715716
doi: 10.1038/s41523-019-0123-9
Vignoli, A. et al. Effect of estrogen receptor status on circulatory immune and metabolomics profiles of HER2-positive breast cancer patients enrolled for neoadjuvant targeted chemotherapy. Cancers (Basel) 12, 314 (2020).
doi: 10.3390/cancers12020314
Cheung, P. K. et al. The applications of metabolomics in the molecular diagnostics of cancer. Expert Rev. Mol. Diagn. 19, 785–793 (2019).
pubmed: 31414918
doi: 10.1080/14737159.2019.1656530
Palli, D. et al. EPIC-Italy. A molecular epidemiology project on diet and cancer: The EPIC-Italy prospective study. Design and baseline characteristics of participants. Tumori 89, 586–593 (2003).
pubmed: 14870823
doi: 10.1177/030089160308900602
Bouzubar, N. et al. Ki67 immunostaining in primary breast cancer: Pathological and clinical associations. Br. J. Cancer 59, 9437 (1989).
doi: 10.1038/bjc.1989.200
Meattini, I. et al. Impact of hormonal status on outcome of ductal carcinoma in situ treated with breast-conserving surgery plus radiotherapy: Long-term experience from two large-institutional series. Breast 33, 139–144. https://doi.org/10.1016/j.breast.2017.03.017 (2017).
doi: 10.1016/j.breast.2017.03.017
pubmed: 28384565
Masala, G. et al. Mammographic breast density and breast cancer risk in a Mediterranean population: A nested case–control study in the EPIC Florence cohort. Breast Cancer Res. Treat. 164, 467–473 (2017).
pubmed: 28478611
doi: 10.1007/s10549-017-4274-9
American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS) 4th edn. (American College of Radiology, 2003).
Ghini, V., Quaglio, D., Luchinat, C. & Turano, P. NMR for sample quality assessment in metabolomics. New Biotechnol. 52, 25–34 (2019).
doi: 10.1016/j.nbt.2019.04.004
Jiménez, B. et al. Quantitative lipoprotein subclass and low molecular weight metabolite analysis in human serum and plasma by 1H NMR spectroscopy in a multilaboratory trial. Anal. Chem. 90, 11962–11971 (2018).
pubmed: 30211542
doi: 10.1021/acs.analchem.8b02412
His, M. et al. Prospective analysis of circulating metabolites and breast cancer in EPIC. BMC Med. 17, 178 (2019).
pubmed: 31547832
pmcid: 6757362
doi: 10.1186/s12916-019-1408-4
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289–300 (1995).
Xia, J., Mandal, R., Sinelnikov, I. V., Broadhurst, D. & Wishart, D. S. MetaboAnalyst 20—A comprehensive server for metabolomic data analysis. Nucleic Acids Res. 40, W127–W133 (2012).
pubmed: 22553367
pmcid: 3394314
doi: 10.1093/nar/gks374
Chong, J. & Xia, J. Using MetaboAnalyst 4.0 for metabolomics data analysis, interpretation, and integration with other omics data. Methods Mol. Biol. 2104, 337–360 (2020).
pubmed: 31953825
doi: 10.1007/978-1-0716-0239-3_17
Li, C. et al. 1H NMR-based metabolomics reveals the antitumor mechanisms of triptolide in BALB/c mice bearing CT26 tumors. Front. Pharmacol. 10, 1175 (2019).
pubmed: 31680959
pmcid: 6798008
doi: 10.3389/fphar.2019.01175
Bi, X. & Henry, C. J. Plasma-free amino acid profiles are predictors of cancer and diabetes development. Nutr. Diabetes 7, e249–e249 (2017).
pubmed: 28287627
pmcid: 5380892
doi: 10.1038/nutd.2016.55
Hart, C. D. et al. Serum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicenter population. Clin. Cancer Res. 23, 1422–1431 (2017).
pubmed: 28082280
pmcid: 5695865
doi: 10.1158/1078-0432.CCR-16-1153
Garcia-Estevez, L. & Moreno-Bueno, G. Updating the role of obesity and cholesterol in breast cancer. Breast Cancer Res. 21, 35 (2019).
pubmed: 30823902
pmcid: 6397485
doi: 10.1186/s13058-019-1124-1
Lu, C. W. et al. VLDL and LDL, but not HDL, promote breast cancer cell proliferation, metastasis and angiogenesis. Cancer Lett. 388, 130–138 (2017).
pubmed: 27940127
doi: 10.1016/j.canlet.2016.11.033
Daniëls, V. W. et al. Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment. PLoS ONE 9, e106913 (2014).
pubmed: 25215509
pmcid: 4162556
doi: 10.1371/journal.pone.0106913
Chen, W. Y. et al. Analyzing the differentially expressed genes and pathway cross-talk in aggressive breast cancer. J. Obstet. Gynaecol. Res. 41, 132–140 (2015).
pubmed: 25227254
doi: 10.1111/jog.12495
Zhu, X. et al. Identification of collaboration patterns of dysfunctional pathways in breast cancer. Int. J. Clin. Exp. Pathol. 7, 3853–3864 (2014).
pubmed: 25120762
pmcid: 4128997
Bai, J. et al. Screening of core genes and pathways in breast cancer development via comprehensive analysis of multi gene expression datasets. Oncol. Lett. 18, 5821–5830 (2019).
pubmed: 31788055
pmcid: 6865771
Ludwig, J. A. & Weinstein, J. N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5, 845–856 (2005).
pubmed: 16239904
doi: 10.1038/nrc1739
Geck, R. C. & Toker, A. Nonessential amino acid metabolism in breast cancer. Adv. Biol. Regul. 62, 11–17 (2016).
pubmed: 26838061
doi: 10.1016/j.jbior.2016.01.001
Opstal-van Winden, A. W. et al. A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int. J. Mol. Sci. 13, 13587–13604 (2012).
pubmed: 23202969
pmcid: 3497343
doi: 10.3390/ijms131013587
Lécuyer, L. et al. NMR metabolomic signatures reveal predictive plasma metabolites associated with long-term risk of developing breast cancer. Int. J. Epidemiol. 47(2), 484–494 (2018).
pubmed: 29365091
doi: 10.1093/ije/dyx271
Yang, L. et al. Application of metabolomics in the diagnosis of breast cancer: A systematic review. J. Cancer 11(9), 2540–2551 (2020).
pubmed: 32201524
pmcid: 7066003
doi: 10.7150/jca.37604
Yeh, C. Y. et al. Assessing biological and technological variability in protein levels measured in pre-diagnostic plasma samples of women with breast cancer. Biomark. Res. 5, 30 (2017).
pubmed: 29075496
pmcid: 5645980
doi: 10.1186/s40364-017-0110-y